Time filter

Source Type

Toronto, Canada

News Article
Site: www.scientificcomputing.com

Cray is partnering with the Alan Turing Institute, the new U.K. data science research organization in London, to help the U.K. as it increases research in data science to benefit research and industry. Earlier this month Fiona Burgess, U.K. senior account manager, and I attended the launch of the institute. At the event, U.K. Minister for Science and Universities Jo Johnson paid tribute to Turing and his work. Institute director Professor Andrew Blake told the audience that the Turing Institute is about much more than just big data — it is about data science, analyzing that data and gaining a new understanding that leads to decisions and actions. Alan Turing was a pioneering British computer scientist. He has become a household name in the U.K. following publicity surrounding his role in breaking the Enigma machine ciphers during the Second World War. This was a closely guarded secret until a few years ago, but has recently become the subject of numerous books and several films. Turing was highly influential in the development of computer science, providing a formalization of the concepts of algorithm and computation with the Turing machine. After the war, he worked at the National Physical Laboratory, where he designed ACE, one of the first stored-program computers. The Alan Turing Institute is a joint venture between the universities of Cambridge, Edinburgh, Oxford, Warwick, University College London, and the U.K. Engineering and Physical Science Research Council (EPSRC). The Institute received initial funding in excess of £75 million ($110 million) from the U.K. government, the university partners and other business organizations, including the Lloyd’s Register Foundation. The Turing Institute will, among other topics, research how knowledge and predictions can be extracted from large-scale and diverse digital data. It will bring together people, organizations and technologies in data science for the development of theory, methodologies and algorithms. The U.K. government is looking to this new Institute to enable the science community, commerce and industry to realize the value of big data for the U.K. economy. Cray will be working with the Turing Institute and EPSRC to provide data analytics capability to the U.K.’s data sciences community.  EPSRC’s ARCHER supercomputer, a Cray XC30 system based at the University of Edinburgh, has been chosen for this work. Much as we worked with NERSC to port Docker to Cray systems, we will be working with ATI to port analytics software to ARCHER and then XC systems generally. ARCHER is currently the largest supercomputer for scientific research in the U.K. — with its recent upgrade ARCHER’s 118,080 cores can access in excess of 300 TB of memory. What sort of problem might need that amount of processing power?  Genomics England is collecting around 200 GB of DNA sequence data from each of 100,000 people. Finding patterns in all this information will be a mammoth task! ATI have put together a wide ranging programme of workshops and data science summits, details of which can be found on their Web site. Duncan Roweth is a principal engineer in the Cray CTO Office in Bristol, U.K.

Van Nieuwpoort I.C.,VU University Amsterdam | Van Bunderen C.C.,VU University Amsterdam | Arwert L.I.,VU University Amsterdam | Franken A.A.M.,Isala Clinics | And 5 more authors.
European Journal of Endocrinology | Year: 2011

Objective: The Dutch National Registry of GH Treatment in Adults was established in 1998 as an initiative of the Ministry of Health. The main goals were to gain more insight into long-term efficacy, safety, and costs of GH therapy (GHT) in adult GH-deficient (GHD) patients in The Netherlands. Methods: Baseline patient characteristics and diagnostic test procedures were evaluated. Results: Until January 2009 in roughly 10 years, 2891 patients (1475 men and 1416 women, mean age 43.5±16.5 years) were registered. GHD was of childhood-onset (CO) in over 20% of the patients and of isolated in 11%. The most common causes of GHD were pituitary tumors and/or their treatment, craniopharyngiomas, and idiopathic GHD. In 85% of the patients, a GH stimulation test was performed, in the majority an insulin tolerance test (ITT) (49%) or a combined GHRH-arginine test (25%). In 12% of the patients, IGF1 levels were ≤-2 S.D. combined with two or more additional pituitary hormone deficits, and in 2%, it concerned patients with CO-GHD continuing GHT in adulthood. Over the years, the test of first choice shifted from ITT toward GHRH-arginine test. Conclusion: Nearly, 2900 patients were included in the nationwide surveillance database of the Dutch National Registry of GH Treatment in Adults until January 2009. Baseline patient characteristics are comparable to that reported previously. In 85% of these patients, the diagnosis of GHD was established by provocative testing, particularly an ITT or a combined GHRH-arginine test, with an evident increase in the percentage of GHRH-arginine tests being performed in the last years. © 2011 European Society of Endocrinology.

Reisenzein R.,University of Greifswald | Hudlicka E.,Psychometrix Associates Inc | Dastani M.,University Utrecht | Gratch J.,University of Southern California | And 4 more authors.
IEEE Transactions on Affective Computing | Year: 2013

The past years have seen increasing cooperation between psychology and computer science in the field of computational modeling of emotion. However, to realize its potential, the exchange between the two disciplines, as well as the intradisciplinary coordination, should be further improved. We make three proposals for how this could be achieved. The proposals refer to: 1) systematizing and classifying the assumptions of psychological emotion theories; 2) formalizing emotion theories in implementation-independent formal languages (set theory, agent logics); and 3) modeling emotions using general cognitive architectures (such as Soar and ACT-R), general agent architectures (such as the BDI architecture) or general-purpose affective agent architectures. These proposals share two overarching themes. The first is a proposal for modularization: deconstruct emotion theories into basic assumptions; modularize architectures. The second is a proposal for unification and standardization: Translate different emotion theories into a common informal conceptual system or a formal language, or implement them in a common architecture. © 2010-2012 IEEE.

Van Bunderen C.C.,VU University Amsterdam | Van Nieuwpoort I.C.,VU University Amsterdam | Arwert L.I.,VU University Amsterdam | Heymans M.W.,VU University Amsterdam | And 4 more authors.
Journal of Clinical Endocrinology and Metabolism | Year: 2011

Context: Adults with GH deficiency (GHD) have a decreased life expectancy. The effect of GH treatment on mortality remains to be established. Objective: This nationwide cohort study investigates the effect of GH treatment on all-cause and cause-specific mortality and analyzes patient characteristics influencing mortality in GHD adults. Design, Setting, and Patients: Patients in the Dutch National Registry of Growth Hormone Treatment in Adults were retrospectively monitored (1985-2009) and subdivided into treatment (n =2229), primary (untreated, n = 109), and secondary control (partly treated, n = 356) groups. Main Outcome Measures: Standardized mortality ratios (SMR) were calculated for all-cause, malignancy, and cardiovascular disease (CVD) mortality. Expected mortality was obtained from cause, sex, calendar year, and age-specific death rates from national death and population counts. Results: In the treatment group, 95 patients died compared to 74.6 expected [SMR 1.27 (95% confidence interval, 1.04-1.56)]. Mortality was higher in women than in men. After exclusion of high-risk patients, the SMR for CVD mortality remained increased in women. Mortality due to malignancies was not elevated. In the control groups mortality was not different from the background population. Univariate analyses demonstrated sex, GHD onset, age, and underlying diagnosis as influencing factors. Conclusions: GHD men receiving GH treatment have a mortality rate not different from the background population. In women, after exclusion of high-risk patients, mortality was not different from the background population except for CVD. Mortality due to malignancies was not elevated in adults receiving GH treatment. Next to gender, the heterogeneous etiology is of influence on mortality in GHD adults with GH treatment. Copyright © 2011 by The Endocrine Society.

Van Varsseveld N.C.,VU University Amsterdam | Van Bunderen C.C.,VU University Amsterdam | Ubachs D.H.H.,VU University Amsterdam | Franken A.A.M.,Isala Clinics | And 3 more authors.
Journal of Clinical Endocrinology and Metabolism | Year: 2015

Context: Radiotherapy is frequently administered as adjuvant treatment in patients with clinically nonfunctioning pituitary adenomas (NFPAs). However, concerns have been raised about potential long-term side effects, including cerebrovascular events (CVEs) and secondary intracranial tumors. Objective: The aim of this study was to analyze the risk of CVEs, secondary intracranial tumors, and mortality in irradiated (IRR) NFPA patients, compared with NFPA patients who were not irradiated (non-IRR). Design, Setting, and Patients: The study cohort included 806 patients with a NFPA from the Dutch National Registry of Growth Hormone Treatment in Adults, a nationwide long-term surveillance study in severe GH-deficient adult patients. IRR patients (n = 456) were compared with non-IRR patients (n = 350). Main Outcome Measures: CVEs, secondary intracranial tumors, and mortality were measured. Results: Sixty-nine subjects developed a CVE. In men, but not in women, the incidence of a CVE was significantly higher in IRR patients than in non-IRR patients (hazard ratio 2.99, 95% confidence interval 1.31-6.79). A secondary intracranial tumor developed in five IRR patients and two non-IRR patients. After adjustment for age, radiotherapy was not associated with mortality. Conclusions: The incidence of secondary intracranial tumors and mortality did not differ between IRR and non-IRR patients. However, a CVE was found significantly more frequently in IRR men but not in women. Further research into the long-term effects of cranial radiotherapy seems mandatory. The potential risks of radiotherapy have to be taken into account when radiotherapy is considered in NFPA patients, and long-term follow-up is recommended. Copyright © 2015 by the Endocrine Society.

Discover hidden collaborations